SUMMARY In a randomised study oftwo drugs for the oral treatment of uncomplicated urogenital and rectal gonorrhoea the therapeutic effect of cefuroxime axetil ester (CAE) and amoxycillin plus clavulanic acid (A+C) was compared. Cefuroxime axetil ester 1 5 g was given to 129 men and 1 18 women. Amoxycillin 3-0 g and clavulanic acid 025 g was given to 131 men and 122 women. Both treatments were combined with probenecid 1 0 g and administered in a single oral dose. Of the 500 patients thus treated, 376 were assessable. In the group taking CAE, failure rates were 0 9% for the men and 0% for the women; and the overall failure rate was 05%. In the group taking A+C the equivalent failure rates were 4-6%, 1-2%, and 3-1%. The differences were not significant Penicillinase producing Neisseria gonorrhoeae (PPNG) was isolated from 5-6% of the assessable patients. All 10 PPNG infections in the group taking CAE and four of 11 PPNG infections in the group taking A+C were cured. These numbers were too small to draw a definite conclusion about the efficacy of both drugs in this type of infection. Postgonococcal urethritis was observed in 35% of the men in the group taking CAE and in 32% ofthose in the group taking A+C. Side effects were noted in 38% of the group taking CAE and 28% of the group taking A+C. Nausea and vomiting were more commonly observed in the group taking CAE; and diarrhoea was more commonly observed in the group taking A+C.
Introduction
During the past few years cefuroxime, administered intramuscularly in a dose of 1-5 g, has been the drug of choice for treating uncomplicated urogenital and rectal gonorrhoea, caused by either penicillinase (PPNG) or non-penicillinase (non-PPNG) producing strains of Neisseria gonorrhoeae in our hospital.'2 Since the introduction of this treatment few treatment failures have been observed in these types of infection. 3 The. rate of cure for oropharyngeal gonorrhoea, however, was disappointing2
A disadvantage of cefuroxime is its parenteral form 314 As both CAE and Augmentin can be given orally in combination with probenecid, and both agents are active in vitro against PPNG as well as non-PPNG, we decided to compare the therapeutic effect of the agents in a single blind randomised study in men and women with uncomplicated urogenital and rectal gonorrhoea.
Patients, materials, and methods Consecutive men and women attending the venereological outpatient department of the University Hospital, Rotterdam, who had urogenital and rectal gonorrhoea, or who were sexual contacts of men with confirmed urethral gonorrhoea, were studied. The trial was designed to treat a sufficient number of patients with doses of CAE or A+C to obtain an assessable quota (200, 100 men and 100 women in each group). Randomisation, stratified by sex, was performd by using sealed envelopes. Patients were either treated with CAE 1*5 g (three tablets of0 5 g), together with probenecid -0 g(two tablets of0 5 g) in a single oral dose, or with a combination of amoxycillin 3 0 g and clavulanic acid 0-25 g (ratio 12:1), together with probenecid 1I0 g (two tablets of 0 5 g) in a single oral dose. Amoxycillin and clavulanic acid were given as a dose of two tablets of Augmentin (0 625 mg each) and four disperse tablets of amoxycillin (0 5 g each).
Patients were excluded from the study for the following reasons: hypersensitivity to penicillin or cephalosporins; recent or simultaneous treatment with other antibiotics; pregnancy or lactation. If the patient vomited within two hours after treatment the results were not analysed. Patients with oropharyngeal gonorrhoea were also excluded from the study.
DIAGNOSIS
The procedures used to detect gonococcal infection have been described previously.' 3 If Gram negative diplococci were found in a Gram stained smear, treatment was started before results of the culture were known, with one ofthe two agents. Female sexual contacts of men with confirmed urethral gonorrhoea were also studied ifthe result ofthe Gram stained smear was negative. Only patients with a positive culture were considered to be assessable. Of all strains isolated before and after treatment, sensitivity to cefuroxime, amoxycillin, amoxycillin plus 2 mg/1 clavulanic acid, amoxycillin plus S mg/l clavulanic acid, penicillin G, and tetracycline were determined by the agar diffusion method. Sensitivities were expressed as minimum inhibitory concentration (MIC) in mg/l. Using twofold dilutions, these antibiotics were tested over the following ranges: 0-005 to 0-64 mg/l for cefuroxime and 0-005 to 0-124 mg/l for the other antibiotics.7 If gonorrhoea persisted after treatment an R Schift, J van Ulsen, M C Ansink-Schipper, et al auxanographic typing, as described previously,8 was also undertaken. If gonococci were found in more than one location we used the urethral and cervical isolates in men and women, respectively, for determining the MIC and auxotype. All isolates were screened for P lactamase production by the chromogenic cephalosporin test (Nitrocephin, Glaxo). At the second visit a two glass urine test was performed on the men. Ifmore than 10 leucocytes per microscopic field (x250) were found in the sediment of the first voided 10-15 ml of urine the patient was considered to have postgonococcal urethritis.
FOLLOW UP
Patients were asked to return one week after treatment when all procedures were repeated. Information was gathered about the possible side effects ofthe drugs by explicitly questioning the patients. If gonorrhoea persisted after treatment a new treatment with the concurrent drug was given (cross over treatment). If gonorrhoea still persisted after the second drug had been given patients received an intramuscular injection of cefuroxime 1-5 g.
ASSESSABLE PATIENTS
Only those patients with a positive culture were assessable, whatever the result of the Gram smear microscopy. Patients who had persistent gonorrhoea but who had had sexual intercourse after treatment were considered to have been reinfected and were therefore not assessed. If gonococcal infection persisted in patients after treatment and the patient had not had intercourse in the intervening period, but there were considerable differences in MIC and auxotype of the strains isolated at the first and second visits, these patients were also considered to be reinfected and were therefore excluded from the study.
This study was approved by our hospital ethical committee.
Results
In all, 260 men and 240 women were treated. Of the men, 129 were treated with CAE and 131 with A+C. Of the women, 118 were treated with CAE and 122 with C+A. The age distribution in each group was similar. The average age of the men was 31 years (range 16-61) in the group taking CAE and 30 years (range 16-59) in the group taking C+A. For the women this was 26 years (range 14-47) in the group taking CAE and 28 years (range 17-47) in the group taking A+C. Of the men, 65% treated with CAE and 74% of those treated with A+C were white, whereas 26% and 19%, respectively, were black Of the women, 84% and 75%, respectively, were white, and 7% and 17%, respectively, were black. Of the 500 in the group taking CAE. In the group taking A+C these figures were 4x6%, 1[2%, and 3x1%, repespectively. These differences were not significant. The only man in the group taking CAE with persistent gonorrhoea had not had intercourse after treatment. At the second visit he had a positive urethral culture; but his strain did not grow at subculture. Though the MIC and auxotype for both strains could not be compared, this case was considered to be a treatment failure. The MIC ofcefuroxime for the first isolation was 0x02 mg/l in this patient.
All 10 patients (four men and six women) in the group taking CAE with a PPNG infection were cured after the first treatment. In the group taking A+C four (three men and one woman) of 11 patients with a PPNG infection had persistent gonorrhoea, which had also been caused by a PPNG strain. If the failure rates of the men, women, and the total number ofpatients in both groups are compared separately (table II) none of the differences in this type of infection was significant (Fisher's exact test p 2 0-09; a = 0'05).
CROSSOVER TREATMENT
In the group taking CAE seven of eight patients with persistent gonorrhoea received further treatment with A+C. One woman received no further treatment with A+C, as there was a possibility of reinfection by a partner who already had been treated with A+C and was not cured. In four of these seven patients the gonococcal infection was cured by A+C. Two of the remaining three patients did not return for review. One man still had urethral gonorrhoea on the third visit. This patient had had intercourse after the second treatment In the group taking A+C, 20 of 22 patients with persistent gonorrhoea were treated with CAE: all 20 patients were cured. One patient refused any further oral treatment. The other patient received a different treatment because of salpingitis. The percentages of patients with postgonoccal urethritis receiving both treatments were high. This implies that further treatment is indicated in a relatively large number of cases, with a drug active against the micro-organisms that cause non-specific urethritis.
Both treatments showed a high proportion of side effects. In treatment with CAE complaints of nausea and vomiting predominated and in treatment with A+C diarrhoea was the major complaint. Other lower doses, especially for treatment with CAE, might reduce the number and nature of side effects.
In our opinion the results of the treatments with CAE and A+C ofuncomplicated urogenital and rectal gonorrhoea were satisfactory. The results of the oral treatment with CAE were even better than those obtained a few years ago with the intramuscular administration of cefuroxime (I 5 g). Apart from the previously mentioned drawbacks, oral treatments with CAE and A+C are a welcome addition to the limited number of other drugs that are available for the oral treatment of urogenital and rectal gonorrhoea. 
